用于卵巢癌前药单一疗法的康普瑞他汀A4-β-半乳糖苷缀合物
Combretastatin A4-β-Galactosyl Conjugates for Ovarian Cancer Prodrug Monotherapy.
作者信息
Doura Tomohiro, Takahashi Kazuaki, Ogra Yasumitsu, Suzuki Noriyuki
机构信息
Graduate School of Pharmaceutical Sciences, Chiba University , 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan.
出版信息
ACS Med Chem Lett. 2017 Jan 20;8(2):211-214. doi: 10.1021/acsmedchemlett.6b00427. eCollection 2017 Feb 9.
Abstract
Chemotherapy for ovarian cancer often causes severe side effects. As candidates for combretastatin A4 (CA4) prodrug for ovarian cancer prodrug monotherapy (PMT), we designed and synthesized two β-galactose-conjugated CA4s (CA4-βGals), CA4-βGal-1 and CA4-βGal-2. CA4 was liberated from CA4-βGals by β-galactosidase, an enzyme more strongly expressed in ovarian cancer cells than normal cells. CA4-βGal-2, which has a self-immolative benzyl linker between CA4 and the β-galactose moiety, was more cytotoxic to ovarian cancer cell lines than CA4-βGal-1 without a linker. Therefore, CA4-βGal-2 can serve as a platform for the design and manufacture of prodrugs for ovarian cancer PMT.
摘要
卵巢癌化疗常常会引发严重的副作用。作为卵巢癌前药单一疗法（PMT）中康普瑞汀A4（CA4）前药的候选药物，我们设计并合成了两种β-半乳糖共轭CA4（CA4-βGal），即CA4-βGal-1和CA4-βGal-2。CA4可通过β-半乳糖苷酶从CA4-βGal中释放出来，该酶在卵巢癌细胞中的表达比正常细胞更强。在CA4和β-半乳糖部分之间具有自毁型苄基连接子的CA4-βGal-2，对卵巢癌细胞系的细胞毒性比没有连接子的CA4-βGal-1更强。因此，CA4-βGal-2可作为设计和制造用于卵巢癌PMT前药的一个平台。
相似文献
1
Combretastatin A4-β-Galactosyl Conjugates for Ovarian Cancer Prodrug Monotherapy.
ACS Med Chem Lett. 2017 Jan 20;8(2):211-214. doi: 10.1021/acsmedchemlett.6b00427. eCollection 2017 Feb 9.
2
Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.
Int J Nanomedicine. 2019 Nov 7;14:8805-8818. doi: 10.2147/IJN.S210938. eCollection 2019.
3
Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
Clin Cancer Res. 2004 Feb 15;10(4):1446-53. doi: 10.1158/1078-0432.ccr-0518-03.
4
Combretastatin A4/poly(-glutamic acid)-graft-PEG conjugates self-assembled to nanoparticles.
Asian J Pharm Sci. 2018 Mar;13(2):191-196. doi: 10.1016/j.ajps.2017.10.001. Epub 2017 Oct 24.
5
A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Acta Biomater. 2017 Apr 15;53:179-189. doi: 10.1016/j.actbio.2017.02.001. Epub 2017 Feb 3.
6
Review of Cytotoxic CA4 Analogues that Do Not Target Microtubules: Implications for CA4 Development.
Mini Rev Med Chem. 2017;17(16):1507-1514. doi: 10.2174/1389557515666160509125829.
7
Nanoparticles Composed of PEGylated Alternating Copolymer-Combretastatin A4 Conjugate for Cancer Therapy.
Macromol Biosci. 2021 Aug;21(8):e2100077. doi: 10.1002/mabi.202100077. Epub 2021 May 24.
8
Anticancer drug released from near IR-activated prodrug overcomes spatiotemporal limits of singlet oxygen.
Bioorg Med Chem. 2016 Apr 1;24(7):1540-9. doi: 10.1016/j.bmc.2016.02.025. Epub 2016 Feb 21.
9
Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug.
Bioorg Med Chem Lett. 2019 Feb 1;29(3):487-490. doi: 10.1016/j.bmcl.2018.12.017. Epub 2018 Dec 10.
10
Covalent functionalization of SWCNT with combretastatin A4 for cancer therapy.
Nanotechnology. 2018 Jun 15;29(24):245101. doi: 10.1088/1361-6528/aab9f2. Epub 2018 Mar 27.
引用本文的文献
1
Glycosidase-activated prodrugs of a cytotoxic iron chelator for targeted cancer therapy.
RSC Med Chem. 2025 Jun 19. doi: 10.1039/d5md00232j.
2
Tandem activated caged galactoside prodrugs: advancing beyond single galactosidase dependence.
Chem Sci. 2025 Mar 18;16(17):7173-7190. doi: 10.1039/d5sc00722d. eCollection 2025 Apr 30.
3
Galactose: A Versatile Vector Unveiling the Potentials in Drug Delivery, Diagnostics, and Theranostics.
Pharmaceuticals (Basel). 2024 Feb 27;17(3):308. doi: 10.3390/ph17030308.
4
An Unrevealed Molecular Function of Corannulene Buckybowl Glycoconjugates in Selective Tumor Annihilation by Targeting the Cancer-Specific Warburg Effect.
Adv Sci (Weinh). 2022 Apr;9(10):e2105315. doi: 10.1002/advs.202105315. Epub 2022 Mar 7.
5
More Than Resveratrol: New Insights into Stilbene-Based Compounds.
Biomolecules. 2020 Jul 27;10(8):1111. doi: 10.3390/biom10081111.
6
Nanotechnology for angiogenesis: opportunities and challenges.
Chem Soc Rev. 2020 Jul 21;49(14):5008-5057. doi: 10.1039/c8cs01021h. Epub 2020 Jun 15.
7
Single-Chain Nanoparticle Delivers a Partner Enzyme for Concurrent and Tandem Catalysis in Cells.
J Am Chem Soc. 2020 Mar 11;142(10):4565-4569. doi: 10.1021/jacs.9b13997. Epub 2020 Feb 28.
8
Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents.
Medchemcomm. 2017 Jul 4;8(8):1592-1603. doi: 10.1039/c7md00227k. eCollection 2017 Aug 1.
9
Deciphering the origins of molecular toxicity of combretastatin A4 and its glycoconjugates: interactions with major drug transporters and their safety profiles and .
Medchemcomm. 2017 Jun 12;8(7):1542-1552. doi: 10.1039/c7md00246g. eCollection 2017 Jul 1.
本文引用的文献
1
Self-immolative spacers: kinetic aspects, structure-property relationships, and applications.
Angew Chem Int Ed Engl. 2015 Jun 22;54(26):7492-509. doi: 10.1002/anie.201500088. Epub 2015 Jun 5.
2
Sensitive β-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo.
Nat Commun. 2015 Mar 13;6:6463. doi: 10.1038/ncomms7463.
3
Possible role of α-mannosidase and β-galactosidase in larynx cancer.
Contemp Oncol (Pozn). 2012;16(2):154-8. doi: 10.5114/wo.2012.28795. Epub 2012 May 29.
4
Lipophilicity in drug discovery.
Expert Opin Drug Discov. 2010 Mar;5(3):235-48. doi: 10.1517/17460441003605098.
5
A comparative study of the self-immolation of para-aminobenzylalcohol and hemithioaminal-based linkers in the context of protease-sensitive fluorogenic probes.
Org Biomol Chem. 2010 Apr 21;8(8):1777-80. doi: 10.1039/b926316k.
6
Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs.
Bioorg Med Chem Lett. 2009 Dec 15;19(24):6948-51. doi: 10.1016/j.bmcl.2009.10.064. Epub 2009 Oct 20.
7
The biology of ovarian cancer: new opportunities for translation.
Nat Rev Cancer. 2009 Jun;9(6):415-28. doi: 10.1038/nrc2644.
8
Activity of lysosomal exoglycosidases in human gliomas.
J Neurooncol. 2006 Dec;80(3):243-9. doi: 10.1007/s11060-006-9188-z. Epub 2006 May 19.
9
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
N Engl J Med. 2006 Jan 5;354(1):34-43. doi: 10.1056/NEJMoa052985.
10
Cancer of the ovary.
N Engl J Med. 2004 Dec 9;351(24):2519-29. doi: 10.1056/NEJMra041842.
Zotero 插件